Arm's Recent Pullback Is a Gift for Long-Term Investors at Current Levels

Arm’s ADRs pulled back after a blowout rally, but 24/7 Wall St. reiterates a BUY with a $315.98 12-month target vs. $277.01 current price (~14.07% upside, 90% confidence). The recent catalyst was a strong fiscal 2026 close, including Q4 revenue of $1.49B (+20.06%) and non-GAAP EPS of $0.60 beating the $0.5793 consensus, supported by 29% license revenue growth and data center royalties more than doubling. The main risks are valuation (trailing P/E ~356) and margin compression (operating margin 52.8% to 49.1%, -370 bps), while the bull case hinges on >$2B of AGI CPU customer demand in FY2027-28 and continued Armv9 royalty mix expansion.

Analysis

The key market mechanism is not the headline pullback itself but the gap between near-term proof and long-dated embedded expectations. ARM is priced like a scarce AI infrastructure tollbooth, so the next 1-2 earnings prints matter more than the 12-month target: if management does not convert “design demand” into a visible royalty ramp, the multiple can de-rate quickly despite decent growth. That makes the stock more of a duration trade than a fundamentals trade in the next 30-60 days.

Relative winners are the hyperscaler silicon programs that can diversify away from x86, but they are also the customers most exposed to higher IP take-rates if ARM’s ecosystem becomes unavoidable. NVDA is the cleanest second-order beneficiary because ARM-based CPUs increase the probability that its platform becomes the default AI system architecture, but the economic impact is tiny versus GPU revenue. QCOM is the clearest loser: even without litigation noise, ARM’s valuation premium versus QCOM invites investors to short the lower-multiple licensing proxy as a hedge against any disappointment in ARM’s monetization cadence.

The contrarian risk is that the market is underpricing the lag between architecture wins and royalty dollars. The current reset may be mostly momentum unwinding, not a thesis break, and if late-July commentary tightens the link between AGI CPU demand and FY27/FY28 revenue, the stock can re-rate sharply. What falsifies the bullish case is not just a miss, but another step-down in RPO/margin leverage or any sign that customer demand is being pulled forward without translating into binding commitments; that would likely compress the premium multiple over the next 1-3 months.

Key Decisions for Investors

• Buy ARM only on post-earnings confirmation of royalty conversion; use a staged entry over the next 2-6 weeks, with the thesis invalidated if RPO/margin leverage deteriorates again. Risk/reward is acceptable only if the next print shows a clearer monetization bridge to FY27-28 demand.
• Prefer an ARM/NVDA long-long basket over outright ARM beta if expressing the AI-CPU theme; NVDA offers better earnings visibility, while ARM provides the embedded-IP leverage. Use this as a relative-value expression for the next 3-6 months.
• Short QCOM against ARM into the late-July event as a valuation-and-litigation hedge. If ARM disappoints, QCOM should hold up better on lower multiple; if ARM confirms the AI CPU ramp, the spread should widen. Reassess if QCOM litigation risk is explicitly de-risked.
• If you want convexity, buy ARM 3-6 month call spreads instead of stock to control downside from multiple compression. This is only attractive if you expect an earnings upside surprise or a stronger-than-expected guidance tone.
• Set a watch item for any sign that hyperscaler custom silicon adoption is broadening beyond a single customer. A multi-customer inflection would support a higher multiple; absent that, treat the recent rally as potentially overextended.